CY1112778T1 - Υποκατασταθεισα φαινοξυ ν-αλκυλιωμενη θειαζολεδινοδιονη ως ρυθμιστης υποδοχεων σχετιζομενων με υποδοχεα οιστρογονων α - Google Patents
Υποκατασταθεισα φαινοξυ ν-αλκυλιωμενη θειαζολεδινοδιονη ως ρυθμιστης υποδοχεων σχετιζομενων με υποδοχεα οιστρογονων αInfo
- Publication number
- CY1112778T1 CY1112778T1 CY20121100232T CY121100232T CY1112778T1 CY 1112778 T1 CY1112778 T1 CY 1112778T1 CY 20121100232 T CY20121100232 T CY 20121100232T CY 121100232 T CY121100232 T CY 121100232T CY 1112778 T1 CY1112778 T1 CY 1112778T1
- Authority
- CY
- Cyprus
- Prior art keywords
- arthritis
- disease
- cartilage
- chondrosarcoma
- receptor
- Prior art date
Links
- 102000015694 estrogen receptors Human genes 0.000 title 1
- 108010038795 estrogen receptors Proteins 0.000 title 1
- -1 phenoxy N-alkylated thiazolidinedione Chemical class 0.000 title 1
- 108091006073 receptor regulators Proteins 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
- 206010003246 arthritis Diseases 0.000 abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 208000005243 Chondrosarcoma Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 210000000845 cartilage Anatomy 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 201000001421 hyperglycemia Diseases 0.000 abstract 2
- 230000011164 ossification Effects 0.000 abstract 2
- 208000002574 reactive arthritis Diseases 0.000 abstract 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
- 206010003267 Arthritis reactive Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010007710 Cartilage injury Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010027452 Metastases to bone Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 208000000112 Myalgia Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
- 208000033464 Reiter syndrome Diseases 0.000 abstract 1
- 208000025747 Rheumatic disease Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 230000022159 cartilage development Effects 0.000 abstract 1
- 208000017568 chondrodysplasia Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000019439 energy homeostasis Effects 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 208000005368 osteomalacia Diseases 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 230000000306 recurrent effect Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 230000000552 rheumatic effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89345807P | 2007-03-07 | 2007-03-07 | |
| EP08731517A EP2132188B1 (en) | 2007-03-07 | 2008-03-06 | Substituted phenoxy n-alkylated thiazoledinedione as estrogen related receptor-alpha modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1112778T1 true CY1112778T1 (el) | 2016-02-10 |
Family
ID=39720674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100232T CY1112778T1 (el) | 2007-03-07 | 2012-03-07 | Υποκατασταθεισα φαινοξυ ν-αλκυλιωμενη θειαζολεδινοδιονη ως ρυθμιστης υποδοχεων σχετιζομενων με υποδοχεα οιστρογονων α |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8119669B2 (enExample) |
| EP (1) | EP2132188B1 (enExample) |
| JP (1) | JP2010520307A (enExample) |
| KR (1) | KR20090118103A (enExample) |
| CN (1) | CN101679326B (enExample) |
| AR (1) | AR065656A1 (enExample) |
| AT (1) | ATE537157T1 (enExample) |
| AU (1) | AU2008222749A1 (enExample) |
| BR (1) | BRPI0808662B8 (enExample) |
| CA (1) | CA2679965A1 (enExample) |
| CL (1) | CL2008000669A1 (enExample) |
| CY (1) | CY1112778T1 (enExample) |
| DK (1) | DK2132188T3 (enExample) |
| EA (1) | EA200970838A1 (enExample) |
| ES (1) | ES2377165T3 (enExample) |
| HR (1) | HRP20120160T1 (enExample) |
| IL (1) | IL200758A0 (enExample) |
| MX (1) | MX2009009519A (enExample) |
| NZ (1) | NZ579418A (enExample) |
| PL (1) | PL2132188T3 (enExample) |
| PT (1) | PT2132188E (enExample) |
| RS (1) | RS52247B (enExample) |
| SI (1) | SI2132188T1 (enExample) |
| TW (1) | TW200902507A (enExample) |
| WO (1) | WO2008109731A2 (enExample) |
| ZA (1) | ZA200906953B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途 |
| US7846953B2 (en) * | 2007-03-07 | 2010-12-07 | Janssen Pharmaceutica, Nv | Substituted phenoxy thiazolidinediones as estrogen related receptor-α modulators |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| KR20100065191A (ko) | 2007-09-14 | 2010-06-15 | 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 | １,３-이치환된 ４-(아릴-ｘ-페닐)-１ｈ-피리딘-２-온 |
| KR20100080597A (ko) | 2007-09-14 | 2010-07-09 | 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 | １,３-이치환된-４-페닐-1ｈ-피리딘-2-온 |
| CA2696948C (en) | 2007-09-14 | 2013-04-30 | Jose Maria Cid-Nunez | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones |
| EP2220083B1 (en) | 2007-11-14 | 2017-07-19 | Janssen Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| WO2009105621A1 (en) * | 2008-02-22 | 2009-08-27 | The Ohio State University Research Foundation | Androgen receptot-ablative agents |
| CA2735764C (en) | 2008-09-02 | 2016-06-14 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| AU2009304293B2 (en) | 2008-10-16 | 2012-04-26 | Addex Pharma S.A. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| BRPI0921333A2 (pt) | 2008-11-28 | 2015-12-29 | Addex Pharmaceuticals Sa | derivados de indol e benzoxazina como moduladores de receptores de glutamato metabotrópicos |
| NZ596078A (en) | 2009-05-12 | 2013-06-28 | Janssen Pharmaceuticals Inc | 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| EA020671B1 (ru) | 2009-05-12 | 2014-12-30 | Янссен Фармасьютикалз, Инк. | ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2 |
| JP2011057644A (ja) * | 2009-09-14 | 2011-03-24 | Sumitomo Chemical Co Ltd | ３型１７β−ヒドロキシステロイドデヒドロゲナーゼを阻害するための化合物の使用およびそのための医薬組成物 |
| JP2011057643A (ja) * | 2009-09-14 | 2011-03-24 | Sumitomo Chemical Co Ltd | ３型１７β−ヒドロキシステロイドデヒドロゲナーゼを阻害するための化合物の使用およびそのための医薬組成物 |
| AU2011218190A1 (en) | 2010-02-17 | 2012-09-06 | Janssen Pharmaceutica Nv | Aminothiazolones as estrogen related receptor-alpha modulators |
| CA2815002C (en) | 2010-11-08 | 2019-10-22 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| EP2643320B1 (en) | 2010-11-08 | 2015-03-04 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| CN103298810B (zh) | 2010-11-08 | 2016-03-16 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| WO2012153775A1 (ja) * | 2011-05-10 | 2012-11-15 | 国立大学法人神戸大学 | Ras機能阻害作用を有するチオキソチアゾリジン誘導体 |
| TW201311679A (zh) | 2011-08-04 | 2013-03-16 | Takeda Pharmaceutical | 含氮雜環化合物 |
| CN102949364A (zh) * | 2011-08-30 | 2013-03-06 | 天津药物研究院 | 一种含有效成分盐酸维拉佐酮的缓释片 |
| CN106267210A (zh) | 2012-03-26 | 2017-01-04 | 日本化学药品株式会社 | 骨·软组织中产生的巨细胞性肿瘤或软骨肉瘤的预防或治疗剂 |
| WO2014060477A1 (en) * | 2012-10-17 | 2014-04-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and treating bone metastases in prostate cancer patients |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| EP3050573B1 (en) | 2013-09-25 | 2019-12-11 | Nippon Chemiphar Co., Ltd. | Zaltoprofen for preventing metastasis of giant cell tumor that occurs in bone or soft parts, metastasis of chondrosarcoma, or metastasis of osteosarcoma |
| KR102414246B1 (ko) | 2014-01-21 | 2022-06-27 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
| LT3431106T (lt) | 2014-01-21 | 2021-02-10 | Janssen Pharmaceutica Nv | Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US10071164B2 (en) * | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| AU2016349781A1 (en) | 2015-11-02 | 2018-05-10 | Yale University | Proteolysis targeting chimera compounds and methods of preparing and using same |
| EP4316477A1 (en) * | 2018-08-22 | 2024-02-07 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Methods for treating cardiac valve disease |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| CN112538038B (zh) * | 2019-09-20 | 2022-05-20 | 暨南大学 | 2-吲哚酮类ERRα反向激动剂及其药物组合物和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5037842A (en) * | 1990-06-05 | 1991-08-06 | Pfizer Inc. | Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents |
| JP2001072592A (ja) * | 1999-07-01 | 2001-03-21 | Kyowa Hakko Kogyo Co Ltd | テロメラーゼ阻害剤 |
| AU6340600A (en) * | 1999-07-01 | 2001-01-22 | Geron Corporation | Telomerase inhibitors and methods of their use |
| AU5702201A (en) | 2000-04-13 | 2001-10-30 | Mayo Foundation | Abeta<sub>42</sub> lowering agents |
| DE10131899A1 (de) | 2001-07-04 | 2003-02-27 | Boehringer Ingelheim Pharma | In vitro-Screening-Assay für gamma-Secretase |
| AU2003291613B2 (en) * | 2002-04-30 | 2007-09-27 | Merck & Co., Inc. | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers |
| EP1398029A1 (en) | 2002-09-10 | 2004-03-17 | LION Bioscience AG | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives |
| WO2006004555A1 (en) | 2004-06-30 | 2006-01-12 | Paysetter Pte Ltd | System and method for facilitating transfer of physical money and/or credit |
| WO2006019741A1 (en) * | 2004-07-14 | 2006-02-23 | Janssen Pharmaceutica N.V. | Arylidenes for the treatment of estrogen related receptor-alpha mediated diseases |
| JP4931824B2 (ja) | 2004-10-22 | 2012-05-16 | エグゼリクシス， インコーポレイテッド | 薬学的組成物 |
-
2008
- 2008-03-06 AU AU2008222749A patent/AU2008222749A1/en not_active Abandoned
- 2008-03-06 PL PL08731517T patent/PL2132188T3/pl unknown
- 2008-03-06 JP JP2009552883A patent/JP2010520307A/ja active Pending
- 2008-03-06 ES ES08731517T patent/ES2377165T3/es active Active
- 2008-03-06 DK DK08731517.2T patent/DK2132188T3/da active
- 2008-03-06 BR BRPI0808662A patent/BRPI0808662B8/pt not_active IP Right Cessation
- 2008-03-06 SI SI200830561T patent/SI2132188T1/sl unknown
- 2008-03-06 EP EP08731517A patent/EP2132188B1/en active Active
- 2008-03-06 CA CA002679965A patent/CA2679965A1/en not_active Abandoned
- 2008-03-06 US US12/043,291 patent/US8119669B2/en not_active Expired - Fee Related
- 2008-03-06 CL CL2008000669A patent/CL2008000669A1/es unknown
- 2008-03-06 PT PT08731517T patent/PT2132188E/pt unknown
- 2008-03-06 MX MX2009009519A patent/MX2009009519A/es active IP Right Grant
- 2008-03-06 NZ NZ579418A patent/NZ579418A/en not_active IP Right Cessation
- 2008-03-06 HR HR20120160T patent/HRP20120160T1/hr unknown
- 2008-03-06 AT AT08731517T patent/ATE537157T1/de active
- 2008-03-06 RS RS20120106A patent/RS52247B/sr unknown
- 2008-03-06 EA EA200970838A patent/EA200970838A1/ru unknown
- 2008-03-06 TW TW097107936A patent/TW200902507A/zh unknown
- 2008-03-06 WO PCT/US2008/056018 patent/WO2008109731A2/en not_active Ceased
- 2008-03-06 KR KR1020097020832A patent/KR20090118103A/ko not_active Withdrawn
- 2008-03-06 CN CN2008800153616A patent/CN101679326B/zh not_active Expired - Fee Related
- 2008-03-07 AR ARP080100963A patent/AR065656A1/es not_active Application Discontinuation
-
2009
- 2009-09-06 IL IL200758A patent/IL200758A0/en unknown
- 2009-10-06 ZA ZA2009/06953A patent/ZA200906953B/en unknown
-
2012
- 2012-01-10 US US13/346,808 patent/US9034852B2/en not_active Expired - Fee Related
- 2012-03-07 CY CY20121100232T patent/CY1112778T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9034852B2 (en) | 2015-05-19 |
| JP2010520307A (ja) | 2010-06-10 |
| NZ579418A (en) | 2012-01-12 |
| WO2008109731A2 (en) | 2008-09-12 |
| AR065656A1 (es) | 2009-06-24 |
| TW200902507A (en) | 2009-01-16 |
| ZA200906953B (en) | 2010-12-29 |
| US8119669B2 (en) | 2012-02-21 |
| CN101679326B (zh) | 2012-12-12 |
| DK2132188T3 (da) | 2012-02-27 |
| WO2008109731A3 (en) | 2008-11-27 |
| BRPI0808662B8 (pt) | 2021-05-25 |
| RS52247B (sr) | 2012-10-31 |
| KR20090118103A (ko) | 2009-11-17 |
| BRPI0808662A2 (pt) | 2014-08-26 |
| EP2132188A2 (en) | 2009-12-16 |
| ES2377165T3 (es) | 2012-03-23 |
| HRP20120160T1 (hr) | 2012-03-31 |
| IL200758A0 (en) | 2010-05-17 |
| PT2132188E (pt) | 2012-02-13 |
| CL2008000669A1 (es) | 2008-11-03 |
| EA200970838A1 (ru) | 2010-02-26 |
| EP2132188B1 (en) | 2011-12-14 |
| SI2132188T1 (sl) | 2012-04-30 |
| AU2008222749A1 (en) | 2008-09-12 |
| US20080286265A1 (en) | 2008-11-20 |
| CN101679326A (zh) | 2010-03-24 |
| MX2009009519A (es) | 2009-11-18 |
| PL2132188T3 (pl) | 2012-05-31 |
| CA2679965A1 (en) | 2008-09-12 |
| BRPI0808662B1 (pt) | 2020-09-29 |
| ATE537157T1 (de) | 2011-12-15 |
| US20120108571A1 (en) | 2012-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP099614A (es) | Fenoxi tiazolidindionas sustituidas como moduladores del receptor alfa relacionado con el estrogeno | |
| MX2009009519A (es) | Fenoxitiazolidinodionas n-alquiladas sustituidas como moduladores de receptor- alfa relacionados con estrogeno. | |
| MX2009009520A (es) | Fenoxiaminotiazolonas sustituidas como moduladores del receptor alfa relacionados con estrogenos. | |
| MX2012009529A (es) | Aminotiazolonas como moduladores de receptores alfa relacionados con el estrógeno. | |
| CY1124985T1 (el) | Αγωνιστες υποδοχεων πεπτιδιου φορμυλιου 2 φαινυλπυρρολιδινονης | |
| CA2599348C (en) | Indole compound and use thereof | |
| Sujith et al. | Regioselective reaction: synthesis and pharmacological study of Mannich bases containing ibuprofen moiety | |
| CY1108752T1 (el) | Παραγωγα πουρινης δρωντα ως αγωνιστες του α2α-υποδοχεα | |
| WO2011103130A8 (en) | Aminothiazolones as estrogen related receptor-alpha modulators | |
| FI3268047T3 (fi) | Uusia amatoksiini-vasta-ainekonjugaatteja | |
| JP2012506473A5 (enExample) | ||
| CY1116589T1 (el) | Παραγωγο κυκλοπεντυλακρυλamιδιου | |
| CA2570619A1 (en) | Imidazole variants as modulators of gaba receptor for the treatment of gi disorders | |
| ES2929799T3 (es) | Compuestos que contienen resto de 2-oxo-1,3,4-tiadiazinan-3-ilo con actividad agonista del receptor EP4 | |
| WO2005115383A3 (en) | Substituted triazoles as modulators of ppar and methods of their preparation | |
| BRPI0712889A2 (pt) | composto, processo e preparação de um composto intermediário, e, composições farmacêutica | |
| BR9907125A (pt) | Novolacs fenólicas com propriedades óticas melhoradas | |
| TW200716566A (en) | Prokineticin 2 receptor antagonists | |
| Refaat et al. | Synthesis and anti-inflammatory activity of certain piperazinylthienylpyridazine derivatives | |
| BRPI0905601A2 (pt) | compostos de etinilindol | |
| PT1435235E (pt) | Utilizacao de acido hidroxioleico e compostos semelhantes na producao de medicamentos | |
| Rao et al. | An efficient reverse Diels–Alder approach for the synthesis of N-alkyl bismaleimides | |
| RU2008107360A (ru) | Ароматические олигоэфиры и способ их получения | |
| Sharma et al. | Synthesis and biological evaluation of amide derivatives of (5, 6-dimethoxy-2, 3-dihydro-1H-inden-1-yl) acetic acid as anti-inflammatory agents with reduced gastrointestinal ulcerogenecity | |
| DK142544B (da) | Analogifremgangsmaade til fremstilling af 2-(n-propargyl-n-phenylamino)-imidazolin-(2)-derivater eller fysiologisk acceptable syreadditionssalte heraf |